Sales from controversial drug discount program rose to $54 billion last year; Generic makers fall short when providing access to low- and middle-income countries

Taking stock of the drug industry, from the lab to the medicine chest

September 29, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Sales from controversial drug discount program rose to $54 billion last year Since the 340B program began 30 years ago, the program has ballooned and fed into the national clash over the cost of medicines. By Ed Silverman STAT+ | Generic makers fall short when providing access to low- and middle-income countries, analysis finds Few of 50 medicines reviewed are registered in poor countries and one company has not filed any drug in any low-income country. By Ed Silverman STAT+ | Unitaid slams J&J over pricing and patents for a tuberculosis drug The group expressed "disappointment" that J&J "ignored the public health community's calls" to improve access to its TB pill. By Ed Silverman Stefani Reynolds/The New York Times via AP STAT+ | GOP senator probes drug discount programs at Cleveland Clinic, Bon Secours The top ranking Republican on the Senate health committee is launching an investigation into two hospitals' use of the 340B program. By John Wilkerson STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser